Arghavan Almony

Dec 13, 2023 | ophthalmologytimes.com | Arghavan Almony |Adrienne K. Scott |Roger A. Goldberg |Carl J. Danzig

December 13, 2023Retina experts deliberate on the role of fluorescein angiography in AMD and discuss initiation of anticomplement therapy for geographic atrophy in conjunction with anti-VEGF therapy for neovascular AMD. Arghavan Almony, MD: That was a great case. Let me step back for a second to the diagnosis. We had not 1 but 2 FAs [fluorescein angiograms] in this case. I think a lot of retina specialists are going away from FA more and more for many reasons.

Dec 13, 2023 | ophthalmologytimes.com | Arghavan Almony |Adrienne K. Scott |Roger A. Goldberg |Carl J. Danzig

Arghavan Almony, MD: We’ll move to our third case. Roger, if you could. Roger Goldberg, MD: I’m pleased to be sharing a case from my good friend and colleague Nate Steinle[, MD] down in Santa Barbara, [California]. This is a patient of his whom he refers to as one of his true VIP patients. [This is] a 71-year-old [woman] with slow-onset blurred vision in both eyes. Here’s the color fundus photo of the right eye, and we see a little bit of [geographic] atrophy present and drusen.

Dec 6, 2023 | ophthalmologytimes.com | Arghavan Almony |Adrienne K. Scott |Roger A. Goldberg |Carl J. Danzig

Arghavan Almony, MD: Let’s move on to the next case. Adrienne, if you could present this case for us. Adrienne Scott, MD: Thank you very much. This is a patient whom I encountered in my clinic. He’s a 73-year-old man [with] a history of long-standing intermediate AMD [age-related macular degeneration]. He came in acutely, [presenting with] a new onset central scotoma in his right eye for [approximately] 1 week. No symptoms in the left [eye]. He has no positive past ocular history.

Nov 29, 2023 | ophthalmologytimes.com | Arghavan Almony |Adrienne K. Scott |Roger A. Goldberg |Carl J. Danzig

Arghavan Almony, MD: Thank you, Carl. That was a great case. When we talk about cases, they’re [usually] unique cases that we don’t often see, but this is something we see every day in our retina clinics. What is your first-line treatment for a patient with PDR [proliferative diabetic retinopathy]? Carl Danzig, MD: My first-line treatment for a patient with PDR is always anti-VEGF or bispecific. In this case, I chose faricimab as a treatment.

Nov 29, 2023 | ophthalmologytimes.com | Arghavan Almony |Adrienne K. Scott |Roger A. Goldberg |Carl J. Danzig

Arghavan Almony, MD: Hello, and welcome to this Ophthalmology Times® Grand Rounds discussion. My name is Arghavan Almony. I’m a retina surgeon at Carolina Eye Associates in Southern Pines, North Carolina. I have 3 copanelists with me today, and I’ll ask them to introduce themselves. Carl Danzig, MD: Thank you. My name is Dr Carl Danzig. I’m a retina specialist at Rand Eye Institute in Deerfield Beach, Florida. Adrienne Scott, MD: Hello, my name is Dr Adrienne Scott.